Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy.

Autor: Chinthrajah RS; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA., Sindher SB; Sean N. Parker Center for Allergy and Asthma Research at Stanford University, Stanford, California, USA., Nadeau KC; Harvard T.H. Chan School of Public Health, Harvard University, Boston, Massachusetts, USA., Leflein JG; Allergy & Immunology Association of Michigan, Ypsilanti, Michigan, USA., Spergel JM; Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania, USA., Petroni DH; Seattle Allergy & Asthma Research Institute, Seattle, Washington, USA., Jones SM; Department of Pediatrics, Division of Allergy and Immunology, University of Arkansas for Medical Sciences and Arkansas Children's Hospital, Little Rock, Arkansas, USA., Casale TB; Division of Allergy & Immunology, University of South Florida, Tampa, Florida, USA., Wang J; Department of Pediatrics, Division of Allergy & Immunology, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Carr WW; Allergy & Asthma Associates of Southern California, Food Allergy Center of Southern California, Southern California Research, Mission Viejo, California, USA., Shreffler WG; Food Allergy Center and Department of Pediatrics, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA., Wood RA; Division of Pediatric Allergy & Immunology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA., Wambre E; Benaroya Research Institute, Seattle, Washington, USA., Liu J; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Akinlade B; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Atanasio A; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Orengo JM; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Hamilton JD; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Kamal MA; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Hooper AT; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA., Patel K; Former Employee, Sanofi, Cambridge, Massachusetts, USA., Laws E; Sanofi, Bridgewater, New Jersey, USA., Mannent LP; Sanofi, Chilly-Mazarin, France., Adelman DC; Department of Medicine, Allergy/Immunology, University of California, San Francisco, California, USA.; Aimmune Therapeutics, Brisbane, California, USA., Ratnayake A; Aimmune Therapeutics, Brisbane, California, USA., Radin AR; Regeneron Pharmaceuticals Inc., Tarrytown, New York, USA.

Publikováno v: Allergy [Allergy] 2024 Dec 14. Date of Electronic Publication: 2024 Dec 14.

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthma.

Autor: Fish JE; Department of Pulmonary Medicine, Thomas Jefferson Hospital, Philadelphia, PA, USA., Karpel JP, Craig TJ, Bensch GW, Noonan M, Webb DR, Silverman B, Schenkel EJ, Rooklin AR, Ramsdell JW, Nathan R, Leflein JG, Grossman J, Graft DF, Gower RG, Garay SM, Frigas E, Degraff AC, Bronsky EA, Bernstein DI, Berger W, Shneyer L, Nolop KB, Harrison JE

Publikováno v: The Journal of allergy and clinical immunology [J Allergy Clin Immunol] 2000 Nov; Vol. 106 (5), pp. 852-60.